RxDoctor Payments Data

Darrin Breaux, MD

Cardiovascular Disease · Baton Rouge, LANPI 1902807167

Payments from drug & device makers

$9,853in general payments, 2019–2025

Across 574 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$981
  • Amgen$973
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$761
  • Pfizer$678
  • Merck$585
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$9,838100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,853 in reported general payments places this provider in the 70th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$700,031
Medicare patients
2,392
Services billed
8,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban879$810,791
XareltoRivaroxaban657$564,970
EntrestoSacubitril/Valsartan651$562,604
FarxigaDapagliflozin Propanediol280$197,611
Repatha SureclickEvolocumab175$124,091
JardianceEmpagliflozin106$73,356
Praluent PenAlirocumab48$41,191
NexletolBempedoic Acid54$32,142
NexlizetBempedoic Acid/Ezetimibe40$25,194
VascepaIcosapent Ethyl39$21,186
Metoprolol Succinate1,536$17,254
Droxidopa15$16,656
VerquvoVericiguat12$14,519
LivaloPitavastatin Calcium25$13,428
BrilintaTicagrelor17$11,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$678$810,791879 claims
Johnson & JohnsonXarelto$1,289$564,970657 claims
NovartisEntresto$981$562,604651 claims
AstraZenecaFarxiga, Brilinta$496$209,194297 claims
Boehringer IngelheimJardiance, Pradaxa$340$76,009117 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$451$57,33594 claims
MerckVerquvo$585$14,51912 claims
Kowa Pharmaceuticals America, Inc.Livalo$160$13,42825 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$111$11,97933 claims
AmgenCorlanor$973$8,65018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →